Kyung Hee University, Seoul, Republic of Korea.
The Catholic University of Korea, Bucheon, Republic of Korea.
Integr Cancer Ther. 2020 Jan-Dec;19:1534735420924711. doi: 10.1177/1534735420924711.
PM014 (HL301) is a standardized herbal mixture derived from a traditional Korean medicine, Chung-Sang-Bo-Ha-Tang. Previously, we reported that PM014 treatment significantly suppressed pulmonary fibrosis, one of the frequent adverse effects of anticancer therapy in lung cancer. Before the clinical application of PM014 in anticancer therapy, the safety and efficacy of PM014 in combination with conventional anticancer drugs should be addressed to determine whether PM014 can be used in lung cancer. Lewis lung cancer-bearing mice were injected with 10 mg/kg of cisplatin or paclitaxel on day 5. Starting on day 7, the mice were administered 200 mg/kg PM014 every 2 days. On day 15, all mice were assessed by biochemical and histological analyses. PM014 did not block the antitumor activity of cisplatin and paclitaxel. Coadministration of PM014 and antitumor agents did not elevate the aspartate transaminase/alanine transaminase ratio or the blood urea nitrogen/creatinine ratio. Histopathological analysis also showed that PM014 did not induce hepatic or renal injury. Moreover, PM014 had no apparent inhibitory effects on drug metabolizing enzymes, indicating that PM014 did not alter the pharmacokinetics of chemotherapeutic drugs. Overall, these data show the safety and compatibility of combination therapy of PM014 and chemotherapies for the treatment of lung cancer.
PM014（HL301）是一种标准化的草药混合物，源自传统的韩国药物——仲景八味汤。此前，我们报道 PM014 治疗可显著抑制肺纤维化，这是肺癌抗癌治疗的常见不良反应之一。在 PM014 用于抗癌治疗的临床应用之前，应确定 PM014 与常规抗癌药物联合应用的安全性和疗效，以确定 PM014 是否可用于肺癌治疗。Lewis 肺癌荷瘤小鼠于第 5 天注射 10mg/kg 的顺铂或紫杉醇。从第 7 天开始，每 2 天给予小鼠 200mg/kg 的 PM014。第 15 天，通过生化和组织学分析评估所有小鼠。PM014 并未阻断顺铂和紫杉醇的抗肿瘤活性。PM014 与抗肿瘤药物联合使用并未升高天冬氨酸转氨酶/丙氨酸转氨酶比值或血尿素氮/肌酐比值。组织病理学分析还表明，PM014 不会引起肝或肾损伤。此外，PM014 对药物代谢酶没有明显的抑制作用，表明 PM014 不会改变化疗药物的药代动力学。总体而言，这些数据表明 PM014 联合化疗治疗肺癌的安全性和相容性。
